Close Menu

NEW YORK (360Dx) – Shares of Laboratory Corporation of America were down 11 percent in morning trading today following the company's announcement that it was lowering its full-year 2018 guidance on the top and bottom lines.

Total revenue growth is expected to be in the range of 9.9 percent to 10.3 percent year over year, down from prior guidance of 10.5 percent to 11 percent growth. Revenue growth for LabCorp Diagnostics is expected to be in the range of 2.1 percent to 2.5 percent, down from prior guidance of 3 percent to 3.5 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.